Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome

Autoimmunity Reviews

Volumn 12, Issue 2, 2012, Pages 230-234

  Staub, Henrique Luiz ^a   Bertolaccini, Maria Laura ^b   Khamashta, Munther A ^b  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Phosphatidylethanolamine; Pregnancy morbidity; Thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; KININOGEN; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLETHANOLAMINE ANTIBODY; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG;

ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; ARTERIAL THROMBOEMBOLISM; CELL INVASION; CEREBROVASCULAR ACCIDENT; CRYOPRECIPITATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FERTILIZATION IN VITRO; FLOW CYTOMETRY; KALLIKREIN KININ SYSTEM; LEG THROMBOSIS; LIVEDO RETICULARIS; LUNG EMBOLISM; MATERNAL HYPERTENSION; MATERNAL MORBIDITY; NONHUMAN; PATHOGENESIS; PREGNANCY TERMINATION; PROTEIN CONFORMATION; REVIEW; SNEDDON SYNDROME; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TROPHOBLAST; VENOUS THROMBOEMBOLISM;

ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; FEMALE; HUMANS; MORBIDITY; PHOSPHATIDYLETHANOLAMINES; PREGNANCY; PREGNANCY COMPLICATIONS; THROMBOEMBOLISM;

EID: 84870251694     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.07.008     Document Type: Review

References (59)

1. Palomo I.G., Segovia F.M., Alarcon M.L., Fuentes B.Y., Pereira J.G., Rojas A., et al. An insight into the pathophysiology of thrombosis in antiphospholipid syndrome. Front Biosci 2007, 12:3093-3103.
2. Meroni P.L., Borghi M.O., Raschi E., Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011, 7:330-339.
3. Ruiz-Irastorza G., Crowther M., Branch W., Khamashta M.A. Antiphospholipid syndrome. Lancet 2010, 376:1498-1509.
4. Gharavi A.E., Harris E.N., Asherson R.A., Hughes G.R.V. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 1987, 46:1-6.
5. Vance J.E. Phosphatidylserine and phosphatidylethanolamine in mammalian cells: two metabolically related aminophospholipids. J Lipid Res 2008, 49:1377-1387.
6. Langley K.E., Kennedy E.P. Energetics of rapid transmembrane movement and of compositional asymmetry of phosphatidylethanolamine in membranes of Bacillus megaterium. Proc Natl Acad Sci U S A 1979, 76:6245-6249.
7. Zhixin L., Wells C.W., North P.E., Kumar S., Duris C.B., McIntyre J.A., et al. Phosphatidylethanolamine at the luminal endothelial surface - implications for hemostasis and thrombotic autoimmunity. Clin Appl Thromb Hemost 2011, 17:158-163.
8. Maskrey B.H., Bermúdez-Fajardo A., Morgan A.H., Stewart-Jones E., Dioszeghy V., Taylor G.W., et al. Activated platelets and monocytes generate four hydroxyphosphatidylethanolamines via lipoxygenase. J Biol Chem 2007, 282:20151-20163.
9. Staub H.L., Harris E.N., Khamashta M.A., Savidge G., Chahade W.H., Hughes G.R. Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis. Ann Rheum Dis 1989, 48:166-169.
10. Staub H.L., Khamashta M.A., Harris E.N., Baguley E., Chahade W.H., Hughes G.R.V. Lupus anticoagulant and anticardiolipin antibodies: the affinity may differ [abstract]. Postgrad Med J 1989, 65:700-701.
11. Rauch J., Tannenbaum M., Tannenbaum H., Ramelson H., Cullis P.R., Tilcock C.P., et al. Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems. J Biol Chem 1986, 261:9672-9677.
12. Khamashta M.A., Harris E.N., Gharavi A.E., Derue G., Gil A., Vázquez J.J., et al. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis 1988, 47:849-854.
13. Berard M., Boffa M.C., Karmochkine M., Aillaud M.F., Juhan-Vague I., Francès C., et al. Plasma reactivity to hexagonal II phase phosphatidylethanolamine is more frequently associated with lupus anticoagulant than with antiphosphatidylethanolamine antibodies. J Lab Clin Med 1993, 122:601-605.
14. Mcintyre J.A., Wagenknecht D.R. Anti-phosphatidylethanolamine (aPE) antibodies: a survey. J Autoimmun 2000, 15:185-193.
15. Boffa M.C., Berard M., Sugi T., McIntyre J.A. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies detected by ELISA. II. Kininogen reactivity. J Rheumatol 1996, 23:1375-1379.
16. Sugi T., Mclntyre J.A. Phosphatidylethanolamine induces specific conformational changes in the kininogens recognizable by antiphosphatidylethanolamine antibodies. Thromb Haemost 1996, 76:354-360.
17. Katsunuma J., Sugi T., Inomo A., Matsubayashi H., Izumi S.I., Makino T. Kininogen domain 3 contains regions recognized by antiphosphatidylethanolamine antibodies. J Thromb Haemost 2003, 1:132-138.
18. Sugi T., McIntyre J.A. Autoantibodies to kininogen-phosphatidylethanolamine complexes augment thrombin-induced platelet aggregation. Thromb Res 1996, 84:97-109.
19. Sugi T., McIntyre J.A. Certain autoantibodies to phosphatidylethanolamine (aPE) recognize factor XI and prekallikrein independently or in addition to the kininogens. J Autoimmun 2001, 17:207-214.
20. Sugi T., Makino T. Antiphospholipid antibodies and kininogens in pathologic pregnancies: a review. Am J Reprod Immunol 2002, 47:283-288.
21. Hayashi Y., Aoki K., Kunimatsu M., Sasaki M., Yagami Y. A sensitive assay for anti-phosphatidylethanol-amine antibody in patients with recurrent fetal loss. Nippon Sanka Fujinka Gakkai Zasshi 1990, 42:1565-1570.
22. Drouvalakis K.A., Neeson P.J., Buchanan R.R. Detection of anti-phosphatidylethanolamine antibodies using flow cytometry. Cytometry 1999, 36:46-51.
23. SanMarco M. ELISA for antiphosphatidylethanolamine antibody detection: high impact of assay buffer on results. J Immunol Methods 2010, 358(1-2):9-16.
24. Drouvalakis K.A., Buchanan R.R. Microtitre plate and assay buffer alter detection of antiphosphatidylethanolamine antibodies in lupus anticoagulant positive plasma. Thromb Res 1999, 94:205-212.
25. Bardin N., Pommier G., Sanmarco M. Can cryoglobulins interfere with the measurement of IgM antiphosphatidylethanolamine antibodies by ELISA?. Thromb Res 2007, 119:441-446.
26. Velayuthaprabhu S., Matsubayashi H., Sugi T., Nakamuram M., Ohnishi Y., Ogura T., et al. A unique preliminary study on placental apoptosis in mice with passive immunization of anti-phosphatidylethanolamine antibodies and anti-factor XII antibodies. Am J Reprod Immunol 2011, 66:373-384.
27. Kucuk O., Gilman-Sachs A., Beamanm K., Lis L.J., Westerman M.P. Antiphospholipid antibodies in sickle cell disease. Am J Hematol 1993, 42:380-383.
28. Sotto A., Bérard M., Bessis D., Porneuf M., Jourdan J., Boffa M.C. Antiphospholipid antibody production during Mediterranean spotted fever. Autoimmunity 1995, 21:123-126.
29. Sokol D.K., McIntyre J.A., Short R.A., Gutt J., Wagenknecht D.R., Biller J., et al. Henoch-Schönlein purpura and stroke: antiphosphatidylethanolamine antibody in CSF and serum. Neurology 2000, 55:1379-1381.
30. Magro C.M., Pope-Harman A., Moh P., Ross P. Primary anti-phospholipid antibody syndrome caused by isolated anti-phosphatidylethanolamine antibodies presenting as cryptogenic fibrosing alveolitis with recurrent pulmonary hemorrhage after single-lung transplantation. J Heart Lung Transplant 2002, 21:1232-1236.
31. Yetman D.L., Kutteh W.H. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Fertil Steril 1996, 66:540-546.
32. Sugi T., Katsunuma J., Izumi S., McIntyre J.A., Makino T. Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses. Fertil Steril 1999, 71:1060-1065.
33. Sher G., Fisch J.D., Maassarani G., Matzner W., Ching W., Chong P. Antibodies to phosphatidylethanolamine and phosphatidylserine are associated with increased natural killer cell activity in non-male factor infertility patients. Hum Reprod 2000, 15:1932-1936.
34. Matsubayashi H., Sugi T., Arai T., Kondo A., Suzuki T., Izumi S., et al. Different antiphospholipid antibody specificities are found in association with early repeated pregnancy loss versus recurrent IVF-failure patients. Am J Reprod Immunol 2001, 46:323-329.
35. Sugi T., Matsubayashi H., Inomo A., Dan L., Makino T. Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss. J Obstet Gynaecol Res 2004, 30:326-332.
36. Sanmarco M., Bardin N., Camoin L., Beziane A., Dignat-George F., Gamerre M., et al. Antigenic profile, prevalence, and clinical significance of antiphospholipid antibodies in women referred for in vitro fertilization. Ann N Y Acad Sci 2007, 1108:457-465.
37. Yamada H., Atsumi T., Kobashi G., Ota C., Kato E.H., Tsuruga N., et al. Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes. J Reprod Immunol 2009, 79:188-195.
38. Obayashi S., Ozaki Y., Sugi T., Kitaori T., Katano K., Suzuki S., et al. Antiphosphatidylethanolamine antibodies might not be an independent risk factor for further miscarriage in patients suffering recurrent pregnancy loss. J Reprod Immunol 2010, 85:186-192.
39. Karmochkine M., Cacoub P., Piette J.C., Godeau P., Boffa M.C. Antiphosphatidylethanolamine antibody as the sole antiphospholipid antibody in systemic lupus erythematosus with thrombosis. Clin Exp Rheumatol 1992, 10:603-605.
40. Karmochkine M., Berard M., Piette J.C., Cacoub P., Aillaud M.F., Harlé J.R., et al. Antiphosphatidylethanolamine antibodies in systemic lupus erythematosus. Lupus 1993, 2:157-160.
41. Balada E., Ordi-Ros J., Paredes F., Villarreal J., Mauri M., Vilardell-Tarrés M. Antiphosphatidylethanolamine antibodies contribute to the diagnosis of antiphospholipid syndrome in patients with systemic lupus erythematosus. Scand J Rheumatol 2001, 30:235-241.
42. Gonzales-Portillo F., McIntyre J.A., Wagenknecht D.R., Williams L.S., Bruno A., Biller J. Spectrum of antiphospholipid antibodies (aPL) in patients with cerebrovascular disease. J Stroke Cerebrovasc Dis 2001, 10:222-226.
43. Kalashnikova L.A., Aleksandrova E.N., Novikov A.A., Dobrynina L.A., Nasonov E.L., Sergeeva E.V., et al. Anti-phosphatidylethanolamine antibodies in patients with Sneddon's syndrome. Klin Med (Mosk) 2005, 83:46-49.
44. Blaise S., Seinturier C., Imbert B., Beani J.C., Carpentier P.H. Thrombosis of legs arteries: imputability of anti-phosphatidylethanolamine antibodies?. Ann Dermatol Venereol 2005, 132(6-7 Pt 1):555-558.
45. Matonti F., Hoffart L., Trichet E., Conrath J., Ridings B. Central retinal vein occlusion and anti-phosphatidylethanolamine antibodies isolation: a case report. Can J Ophthalmol 2010, 5:295-296.
46. Hirmerova J., Ulcova-Gallova Z., Seidlerova J., Filipovsky J., Bibkova K., Micanova Z., et al. Laboratory evaluation of antiphospholipid antibodies in patients with venous thromboembolism. Clin Appl Thromb Hemost 2010, 16:318-325.
47. Berard M., Chantome R., Marcelli A., Boffa M.C. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases. J Rheumatol 1996, 23:1369-1374.
48. Desauw C., Hachulla E., Boumbar Y., Bouroz-Joly J., Ponard D., Arvieux J., et al. Antiphospholipid syndrome with only antiphosphatidylethanolamine antibodies: report of 20 cases. Rev Med Interne 2002, 23:357-363.
49. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite APS. J Thromb Haemost 2006, 4:295-306.
50. Sanmarco M., Boffa M.C. Antiphosphatidylethanolamine antibodies and the antiphospholipid syndrome. Lupus 2009, 18:920-923.
51. Sanmarco M. Is testing for antiphosphatidylethanolamine antibodies clinically useful?. Curr Rheumatol Rep 2011, 13:81-85.
52. Bertolaccini M.L., Roch B., Amengual O., Atsumi T., Khamashta M.A., Hughes G.R. Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome. Br J Rheumatol 1998, 37:1229-1232.
53. Sanmarco M., Gayet S., Alessi M.C., Audrain M., de Maistre E., Gris J.C., et al. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European forum on antiphospholipid antibodies. Thromb Haemost 2007, 97:949-954.
54. Sanmarco M., Alessi M.C., Harle J.R., Sapin C., Aillaud M.F., Gentile S., et al. Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses. Thromb Haemost 2001, 85:800-805.
55. Alessandri C., Conti F., Pendolino M., Mancini R., Valesini G. New autoantigens in the antiphospholipid syndrome. Autoimmun Rev 2011, 10:609-616.
56. Conti F., Alessandri C., Sorice M., Capozzi A., Longo A., Garofalo T., et al. Thin-layer chromatography immunostaining in detecting anti-phospholipid antibodies in seronegative anti-phospholipid syndrome. Clin Exp Immunol 2012, 167:429-437.
57. Rodriguez-Garcia J.L., Bertolaccini M.L., Cuadrado M.J., Sanna G., Ateka-Barrutia O., Khamashta M.A. Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called 'seronegative APS'). Ann Rheum Dis 2012, 71:242-244.
58. Bertolaccini M.L., Amengual O., Atsumi T., Binder W.L., de Laat B., Forastiero R., et al. 'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus 2011, 20:191-205.
59. Sanmarco M. Clinical significance of antiphosphatidylethanolamine antibodies in the so-called "seronegative antiphospholipid syndrome". Autoimmun Rev 2009, 9:90-92.